IDM Obtains a Patent in the USA That Protects Its Therapeutic Approach to Dendritic Cell Based Anti-Cancer Vaccines.
PARIS--(BUSINESS WIRE)--Sept. 5, 2002
Immuno-Designed Molecules, S.A. (IDM) today announces that it has been issued a patent in the United States, concerning blood monocyte-derived antigen presenting cells, which have the characteristics of mature dendritic cells.
This is the first patent in the US which specifically protects IDM's therapeutic approach based on dendritic cells.
These cells are known to be able to prime the immune response and secrete an environment of immunostimulating cytokines. These cells are used in the preparation of IDM's cellular vaccines, including Uvidem(TM) and Eladem(TM). Uvidem is currently in a Phase II trial for the treatment of melanoma and is being developed in collaboration with Sanofi-Synthelabo, while Eladem is in a Phase II trial for the treatment of prostate cancer.
This patent gives general coverage to IDM's dendritic cells meaning it covers their usage and the procedures used to obtain them. The patent is valid until 2019, and IDM is currently awaiting its additional issuance in Europe, Japan, Canada and Australia.
Jean-Loup Romet-Lemonne, President and CEO of IDM, stated, "This new patent strengthens IDM's portfolio which already includes 126 patents, 36 of which have been issued internationally."
IDM - The Immunogenics Company(R)
IDM is a leading biopharmaceutical company developing a new family of immunotherapy products called Cell Drugs to fight cancer and other life-threatening diseases. IDM applies its proprietary technologies to selectively isolate, engineer, expand and activate specific cell populations which are involved in therapeutic vaccination. The Company's products are designed to boost the immune system, destroy residual tumor cells, and immunize patients to prevent tumor recurrence. IDM's most advanced product is in Phase III for the treatment of ovarian cancer.
For more information, please visit IDM's Web site,
IDM Paris Headquarters
172 rue de Charonne
75011 Paris FRANCE
tel +33 (0) 1 40 09 04 11
fax +33 (0) 1 40 09 04 25
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 5, 2002|
|Previous Article:||Intel and Microsoft Collaborate With SAP to Announce Early Access to SAP Solutions On Intel Itanium 2-Based Systems.|
|Next Article:||S&P: 'A+' Rating Assigned to QBE LYON.|